Theravance Biopharma (TBPH) Misses Q1 EPS by 14c

Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($1.10), $0.14 worse than the analyst estimate of ($0.96). Revenue for the quarter came in at $18.4 million versus the consensus estimate of $18.69 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• JPMorgan cuts 2026 box office forecast on slow third quarter
• Financial Select Sector SPDR ETF (XLF) spreader of 20K contracts of July 31 weekly 57 and 59 calls into bank earnings season